Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.
Read Also
- Costner, Gere, Demi Moore: Hollywood icons on Cannes comeback trail
- CoreWeave Raises $7.5 Billion in Debt for AI Computing Push
- Speculation Swirls in Slovakia, With Details About Fico Attack Scant
- Aid trucks begin moving ashore via Gaza pier, U.S. says
- Coppola's long-awaited epic 'Megalopolis' divides Cannes
- China pledges $42 billion in a slew of measures to support the struggling property sector
- Paul McCartney becomes UK's first billionaire musician
- As Supernatural Claims Spread Online, Vatican Updates Its Rules on Them
- Pakistan hit by suspected militant bombing of girl's school in former Taliban stronghold
- Israel rejects South Africa’s ICJ plea for Rafah attack halt
Latest CNBC
- China pledges $42 billion in a slew of measures to support the struggling property sector
- Chinese EV maker Xpeng aims to deliver its first flying car in 2026
- Shares of Cartier owner Richemont climb 6% on record full-year sales, new CEO
- China is a 'critical' global supplier, full decoupling may be impossible, survey shows
- ECB board member reportedly cautions against back-to-back rate cuts, cites 'risk of easing prematurely'
- CNBC's Inside India newsletter: What's next for India's regulators?
- Steve Jobs' former intern reflects on working for the tech mogul: 'I worked 20 yards away from him every day'
- HSBC falls 3% amid reports that top shareholder Ping An is looking to trim its stake
- Affluent consumers are creating a ‘bubble’ at Walmart, warns retailer’s former U.S. CEO Bill Simon
- China retail sales, investment data miss expectations in April